Method of assaying apolipoprotein ai for the in vitro diagnosis of colorectal cancer
AssigneeBiomerieux
InventorsYasemin Ataman-Onal, Jean-Philippe Charrier, Genevieve Choquet-Kastylevsky, Florence Poirier
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for the in vitro diagnosis of colorectal cancer by determining the presence of the Apolipoprotein AI tumor marker in a biological sample taken from a patient suspected of having colorectal cancer, it being understood that the assay is not turbidimetric. Said method can be used for early diagnosis, screening, therapeutic follow-up and prognosis, and also for relapse diagnosis in relation to colorectal cancer.
Claims17
1-4. (canceled)
A method for the in vitro diagnosis of colorectal cancer by determining the presence of the Apolipoprotein AI marker in a biological sample taken from a patient suspected of having colorectal cancer, the sample being remote from the tumor, wherein the assay is not a turbidimetric assay.
A process comprising the use of Apolipoprotein AI for early diagnosis, screening, therapeutic follow-up, prognosis, and relapse diagnosis in relation to colorectal cancer, wherein the process does not comprise a turbidimetric assay.
The process of 14, further comprising the use of at least one other tumor marker selected from the group consisting of Beta2-Microglobulin, Proteasome 20S, Galectin-3, L-Lactate Dehydrogenase Chain B, Calreticulin, Regenerating Islet-Derived Protein 3 Alpha, Tumor-Associated Calcium Signal Transducer 1, Epithelial-Cadherin, CEA, CA19-9, Testosterone, TIMP-1, Intelectin-1, Protein Disulfide Isomerase, Cytokeratin 20, Translationally-Controlled Tumor Protein, (Pro)defensin-A5, and the detection of fecal human hemoglobin.
Dependencies are inferred from the claim text.